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RESEARCH ARTICLE Open Access
High hepatocyte growth factor expression
in primary tumor predicts better overall
survival in male breast cancer
Si-Qi Qiu1,2,3, Johan van Rooijen1,4, Hilde H. Nienhuis1, Bert van der Vegt5, Hetty Timmer-Bosscha1,
Elise van Leeuwen-Stok6, Annemiek M. E. Walenkamp1, Carolien H. M. van Deurzen7, Geertruida H. de Bock8,
Elisabeth G. E. de Vries1 and Carolien P. Schröder1*
Abstract
Background: Breast cancer is rare in men, but management is focused on tumor characteristics commonly found
in female breast cancer. The tumor microenvironment of male breast cancer is less well understood, and insight
may improve male breast cancer management. The hepatocyte growth factor (HGF)/c-MET axis and the stromal
cell-derived factor-1 (CXCL12)/C-X-C chemokine receptor type 4 (CXCR4) axis are prognostic in women with breast
cancer. We aimed to investigate these factors in male breast cancer and correlate them with patient survival.
Methods: From 841 Dutch males with breast cancer who were enrolled in the EORTC 10085/TBCRC/BIG/NABCG
International Male Breast Cancer Program (NCT01101425) and diagnosed between 1990 and 2010, archival primary
tumor samples were collected. Tissue microarrays were constructed with 3 cores per sample and used for
immunohistochemical analysis of HGF, c-MET, CXCL12, and CXCR4. Overall survival (OS) of the patients without
metastases (M0) was analyzed using the Kaplan-Meier method. The value of the markers regarding OS was
determined using univariable and multivariable Cox regression analyses, providing hazard ratios (HRs) and 95%
confidence intervals (95% CIs).
Results: Of 720 out of 841 patients, sufficient tissue was available for analysis; 487 out of 720 patients had M0
disease. Patients with high HGF expression and high CXCL12 expression had a superior OS (low vs high expression
of both markers, 7.5 vs 13.0 years, hazard ratio [HR] 0.64, 95% CI 0.49–0.84, P = 0.001 [HGF]; 9.1 vs 15.3 years, HR 0.63,
95% CI 0.45–0.87, P = 0.005 [CXCL12]). Multivariate analysis identified HGF as an independent predictor for OS (HR
0.64, 95% CI 0.47–0.88, P = 0.001).
Conclusions: HGF and CXCL12 tumor expression appear to identify male breast cancer patients with a relatively
good prognosis. Possibly, this could support male breast cancer-specific management strategies in the future.
Keywords: Male breast cancer, Hepatocyte growth factor (HGF), Stromal cell-derived factor-1 (CXCL12), Prognosis,
Tumor biology
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Background
Breast cancer in men is a rare disease. Although only
0.5–1% of all breast cancers occur in men, the incidence
is slowly rising [1, 2]. Generally, male breast cancer has
more favorable tumor characteristics than female breast
cancer, such as lower tumor grade, a higher incidence of
estrogen receptor (ER) expression, and a lower incidence
of human epidermal growth factor receptor 2 (HER2)
expression [1, 3]. On the other hand, male patients
present with higher stages of disease at first diagnosis
than women [1, 4]. Although the outcome in male breast
cancer is similar compared to women after correction
for age and stage, in general, survival improvement in
men is still lagging behind [1, 4–7]. Due to the lack of
survival data from randomized trials in male breast can-
cer, treatment strategies for this disease are largely based
upon data from studies of treatment for female breast
cancer. In recent years, it becomes clear that the male
breast cancer biology may have distinct properties com-
pared to females [8–11]. Therefore, a better understand-
ing of the breast tumor characteristics in men may help
to improve treatment strategies for male breast cancer.
The tumor microenvironment in female breast cancer
is now recognized as a critical participant in determining
the tumor biology. In this environment, the stromal cell-
derived factor-1 (SDF1, also known as CXCL12)/the C-
X-C chemokine receptor type 4 (CXCR4) axis as well as
the hepatocyte growth factor (HGF)/c-MET axis play a
role in promoting tumor progression and metastasis, as
demonstrated in ex vivo cell experiments and in vivo
mouse models of breast cancer [12–14]. The HGF/c-
MET axis induces several biological responses in cancer
cells, which lead to cell migration, matrix degradation,
invasiveness, and induction of angiogenesis [15]. Moreover,
overexpression of CXCR4, HGF, and c-MET in primary
breast cancer is associated with worse patient out-
comes in females [14, 16–20]. Treatments targeting
CXCR4 and c-MET in female metastatic breast cancer
studied in early-phase clinical trials were tolerated
well, and partial response and stable disease were
observed [21–24].
However, whether the CXCL12/CXCR4 and the HFG/
c-MET axis hold similar significance in male breast can-
cer is unknown. These microenvironment factors are of
interest because the host/environment in male breast
cancer will likely be different from female breast cancer.
In order to gain more insight into the male breast can-
cer tumor and environment biology, we studied a large
male breast cancer cohort from The Netherlands. This
cohort is part of the international EORTC 10085/
TBCRC/BIG/NABCG International Male Breast Cancer
Program (NCT01101425). We aimed to explore the
tumor expression of HGF, c-MET, CXCL12, and CXCR4
and their correlation with patient overall survival (OS).
Methods
Patients
The EORTC 10085/TBCRC/BIG/NABCG International
Male Breast Cancer Program (NCT01101425) was
launched in 2006. This program is a global effort that
aims to improve understanding of the biology of male
breast cancer and to optimize its clinical management.
An important part of this program was to retrospectively
analyze male breast cancer tissue of patients diagnosed
between 1990 and 2010 in 93 centers in nine countries.
A total of 1800 male patients with invasive breast cancer
and an age above 18 years at the time of diagnosis, were
eligible and enrolled in the main study. The present
substudy analyzed the data of the 841 Dutch patients
included. This cohort was identified through the
Netherlands Cancer Registry. Patient, treatment, and
tumor characteristics were collected from the EORTC
database. In the tumor, ER, progesterone receptor (PR),
androgen receptor (AR), HER2 and Ki67 expression,
histological subtype, grade, and lymphovascular invasion
had been previously centrally reviewed [25, 26]. Defini-
tions for positivity of ER, PR, AR, and HER2, and breast
cancer subtype surrogate characterization were reported
earlier for all 1800 enrolled patients [26]. Briefly, ER, PR,
and AR were reported by Allred scores, with positivity
defined as a score ≥ 3 and high positivity as a score of 7 or
8. HER2 status was determined according to the American
Society of Clinical Oncology-College of American Path-
ologist (ASCO-CAP) guidelines [26]. Breast cancer sub-
type surrogates were characterized according to the 2013
St. Gallen consensus guideline, where the low level of
Ki67 expression was reported as the percentage of positive
cells < 20% and high level of Ki67 expression as ≥ 20%
[26]. The archival tissue of all patients was handled
according to the Dutch Code for Proper Use of Human
Tissue (www.fedara.org). According to the Dutch Central
Committee on Research involving Human Subjects, this
retrospective non-interventional study did not require
informed consent from these patients.
Tissue microarray construction and
immunohistochemistry
Paraffin-embedded primary breast cancer tissue was
retrospectively collected by the “Borstkanker Onderzoek
Groep” (BOOG). For each formalin-fixed paraffin-
embedded (FFPE) block, three representative cores were
selected and taken to construct tissue microarrays
(TMA) using an Automated Tissue Arrayer ATA-27
(Beecher Instruments, Inc.) [27]. Four-micrometer-thick
tissue slides were cut from these TMA blocks for immu-
nohistochemical staining of HGF, c-MET, CXCL12, and
CXCR4.
Immunohistochemical staining was performed in one
batch per marker to prevent intensity differences.
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Positive control slides determined with primary anti-
bodies and negative control slides with immunoglobulin
class-matched control sera were included on the liver
for HGF, female breast cancer tissue for c-MET, rectum
for CXCL12, and kidney for CXCR4. Besides this, we
also included intestine, heart, brain, liver, lung, stomach,
kidney, pancreas, placenta, muscle, testis, and tonsil tissues
in each of the TMA slides as the internal control. These tis-
sues express different levels of the studied markers, sup-
porting the specificity of the antibodies. Heat-mediated
antigen retrieval was performed with a microwave in a
citrate buffer (10mM citrate, pH 6.0) for CXCL12 and
Tris-EDTA buffer (pH 8.0) for HGF and c-MET. Antigen
retrieval was not performed for CXCR4 staining. Endogen-
ous peroxidase was blocked with 0.3% H202 in phosphate-
buffered saline (PBS; Cl2H3K2Na3O8P2, pH 7.4). A specific
binding was blocked with human AB serum. Primary anti-
bodies (anti-HGF [28]: AF-294-NA [10 μg/ml], R&D Sys-
tems; anti-c-MET [29]: ab51067 [1.269 μg/ml], anti-CXCR4
[30]: ab10403 [5 μg/ml], anti-CXCL12 [31]: ab25117
[10 μg/ml], all Abcam) were diluted in PBS supplemented
with 1% bovine serum albumin. Horseradish peroxidase
(HRP)-conjugated goat anti-rabbit and HRP-conjugated
rabbit anti-goat antibodies (DAKO) were used as secondary
and tertiary antibodies respectively for CXCL12 and c-
MET staining. HRP-conjugated rabbit anti-goat and HRP-
conjugated goat anti-rabbit antibodies were used as second-
ary and tertiary antibodies (DAKO), respectively, for HGF
staining. Staining was visualized using 3,3′-diaminobenzi-
dine and hematoxylin counterstaining.
The immunohistochemistry slides were digitized with
a Digital Slide Scanner NanoZoomer and were viewed
with NDP software (Hamamatsu, Japan). Only the pa-
tients who had two or more cores containing tumor and
stromal cells were included for analysis. Two observers,
blinded for the clinicopathological characteristics of pa-
tients, scored the digitalized images (SQ and JvR) with
the supervision of a dedicated breast pathologist (BvdV).
CXCL12, HGF, and c-MET staining was scored using a
0–2 scale (0, no staining; 1+, weak staining; 2+, strong
staining), as was the percentage of tumor cells stained
per intensity. Subsequently, H-scores were calculated for
Fig. 1 CONSORT diagram of the studied patients, number of patients with available tissue for each marker, and number of M0 patients per
marker available for survival analysis. BOOG, Borstkanker Onderzoek Groep; EORTC, European Organisation for Research and Treatment of Cancer;
CXCR4, C-X-C chemokine receptor type 4; CXCL12, C-X-C motif chemokine 12; HGF, hepatocyte growth factor; M0, patients without metastases at
diagnosis; M1, patients with metastases at diagnosis; Mx, patients with unknown metastatic status at diagnosis
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each marker by combining the percentage and intensity
(formula used: 1 × percentage of cells with weak staining +
2 × percentage of cells with strong staining). CXCR4
staining was scored as the percentage of tumor cells with
a positive nuclear and with a cytoplasm staining, as the
intensity of CXCR4 staining was too homogeneous to use
the 0–2 scale. The percentages or H-scores from two
observers were averaged to obtain the score for each core.
In case of discrepancy (defined as > 20% difference in per-
centage or H-score), a third observer who was blinded to
the scores obtained from the two observers re-scored the
cores. For these discrepant cores, a consensus score ob-
tained from SQ and JvR was used, based on the scores
from the three observers. The average percentage or H-
score of replicate cores was used as the final score for each
patient. The median percentage or H-score of each stud-
ied marker was used as the cutoff to define low and high
expression. The studied markers were also expressed in
some stromal cells, such as the fibroblasts. However, the
staining intensity of the markers in stromal cells was far
weaker than their staining intensity in the tumor cells.
Therefore, in this study, we did not explore the prognostic
value of the studied markers expressed in the stromal
cells.
Statistical analysis
The categorical variables were described by percentages,
and continuous variables by median and interquartile
range (IQR).
OS was defined as the time between the date of diag-
nosis and the documented date of death due to any
cause. The remaining patients were censored at the last
date known to be alive. OS was only defined within the
subset of M0 patients at diagnosis, as the sample size of
M1 patient group was too small to draw conclusions. Pa-
tients with unknown metastastic status (Mx) at the time
of diagnosis were also excluded from the OS analysis, as
the metastastic status largely influence the patient sur-
vival. Only patients with non-missing status/dates of sur-
vival were used for the OS analysis. The prognostic
value of the markers was determined using univariable
Table 1 Patient and tumor characteristics of 720 male breast
cancer patients with sufficient tumor tissue available for analysis
Characteristics No. (%) % exclude missing
Age at diagnosis
Median (IQR) 67 (58–76) years
ER (Allred score)
0–2 11 (1.5) (1.7)
3–6 47 (6.6) (7.3)
7–8 584 (81.1) (91.0)
Missing 78 (10.8)
PR (Allred score)
0–2 146 (20.3) (23.2)
3–6 252 (35.0) (40.0)
7–8 232 (32.2) (36.8)
Missing 90 (12.5)
AR (Allred score)
0–2 20 (2.8) (3.1)
3–6 62 (8.7) (9.8)
7–8 556 (77.2) (87.1)
Missing 82 (11.4)
HER2 status
Negative 597 (82.9) (94.0)
Positive 31 (4.3) (4.9)
Equivocal 7 (1.0) (1.1)
Missing 85 (11.8)
Ki67
≤ 20% 502 (69.7) (79.1)
> 20% 133 (18.5) (20.9)
Missing 85 (11.8)
Breast cancer subtypes (2013 St. Gallen consensus)
Luminal A-like 270 (37.5) (43.3)
Luminal B-like HER2− 311 (43.2) (49.9)
Luminal B-like HER+ 31 (4.3) (5.0)
HER2+ (non-luminal) 0 (0) (0)
Triple-negative 9 (1.3) (1.4)
Not defined (ER−, PR+) 2 (0.3) (0.3)
Missing 97 (13.5)
Histological type
Invasive ductal 628 (87.2) (88.3)
Invasive lobular 9 (1.3) (1.3)
Others 74 (10.3) (10.4)
Missing 9 (1.3)
Histological grade
I 165 (22.9) (23.2)
II 373 (51.8) (52.5)
III 172 (23.9) (24.2)
Table 1 Patient and tumor characteristics of 720 male breast
cancer patients with sufficient tumor tissue available for analysis
(Continued)
Characteristics No. (%) % exclude missing
Missing 10 (1.4)
Metastatic status at diagnosis
M0 487 (67.6) (94.6)
M1 28 (3.9) (5.4)
Mx 205 (28.5)
AR androgen receptor, ER estrogen receptor, HER2 human epidermal growth
factor receptor 2, IQR interquartile range, M0 no metastasis, M1 with
metastasis, Mx metastatic status unknown, PR progesterone receptor
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and multivariable Cox regression analysis. Variables with
a P value of less than 0.1 in the univariable analysis were
included in the multivariable analysis. We used the list-
wise deletion method for handling missing data. In this
method, an entire sample was excluded from the analysis
if any single value is missing for the variables used in the
multivariable Cox regression analysis. For the studied
markers which were not associated with patient survival
in the univariable analysis, their prognostic values were
further investigated in the preplanned subgroup ana-
lyses. OS was analyzed using the Kaplan-Meier method,
with a log-rank test assessing its difference. All tests and
P values tested two-sided were considered significant
when ≤ 0.05. Statistical analysis was performed using the
Statistical Package for the Social Sciences (SPSS) version
19.0 (SPSS. Inc.).
Results
Patient and tumor characteristics
In 720 out of the 841 patients, sufficient tumor tissue
was available for analysis (Fig. 1). Patient and tumor
characteristics at the time of diagnosis of these 720 pa-
tients are shown in Table 1. The median age at diagnosis
of breast cancer was 67 years (IQR, 58–76 years). Almost
all patients had ER-positive tumors (98.3%), with 91.0%
highly positive. PR positivity was observed in 76.8% and
AR positivity in 96.9% of cases. HER2 positivity was
present in tumors of 31 patients (4.9%). The majority of
patients had a luminal-like breast cancer subtype, with
43.3% luminal A-like and 49.9% luminal B-like HER2−.
There were 487 (67.6%) patients that were free from
metastasis (M0) at the time of diagnosis. The treatment
information of these 487 patients is provided in
Additional file 1. The median follow-up for the M0
patients was 6.5 years (range, 0.04–23.8).
Expression of the studied markers in the primary tumor
The exact number of tumors tested per marker is shown
in Fig. 1. Representative images of positive or negative
expression for CXCR4, and negative, weak, or strong
staining for CXCL12, HGF, and c-MET are shown in
Additional file 2. The concordance rates of the percent-
age/H-score for each TMA core (defined as ≤ 20% differ-
ence in percentage or H-score) among the studied
markers between the two observers are shown in Add-
itional file 3. The percentage of positive cells for CXCR4
expression and H-score for CXCL12, HGF, and c-MET
are demonstrated in Fig. 2. The median CXCR4 expres-
sion per tumor was 50% (IQR, 18–83%) in the cytoplasm
and 11% (IQR, 0–42%) in the nucleus. The median H-
score for the CXCL12 expression in the cytoplasm was
100 (IQR, 83–102) and 100 (IQR, 92–107) for the nu-
cleus expression. The median H-scores for HGF and c-
MET expression were 106 (IQR, 83–133) and 155 (IQR,
130–180), respectively. Information on the heterogeneity
of the studied markers between the cores is provided in
Additional files 4, 5, 6, and 7.
Prognostic value of the studied markers for OS in M0
patients
The exact number of M0 patients with available data for
survival analysis is shown in Fig. 1. Both HGF and
CXCL12 (cytoplasm) expression by tumor cells were
correlated to OS in univariable Cox regression analysis,
and HGF remained significant in the multivariable ana-
lysis (Fig. 3). Median OS was 7.5 years (95% CI, 6.1–8.9)
for patients with HGF low-expressing tumors and 13.0
Fig. 2 The expression of the studied markers in male breast cancer as assessed by immunohistochemistry. CXCR4 is presented as the percentage
of cells with positive staining; CXCL12, HGF, and c-MET are presented as H-score. Each dot represents data for an individual patient. The orange
line indicates the median and interquartile range. The dotted line separates markers on its left side presented as the percentage and markers on
its right side presented as the H-score. CXCR4, C-X-C chemokine receptor type 4; CXCL12, C-X-C motif chemokine 12; HGF, hepatocyte
growth factor
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Fig. 3 Factors associated with overall survival in M0 patients at diagnosis in univariable (a) and multivariable (b) Cox regression analysis. a HGF,
CXCL12 (cytoplasm), age at diagnosis, PR, and pT status are statistically significantly associated with overall survival. b HGF, age at diagnosis, ER,
and pT status are independent predictors for overall survival. AR, androgen receptor; CI, confidence interval; CXCR4, C-X-C chemokine receptor
type 4; CXCL12, C-X-C motif chemokine 12; ER, estrogen receptor; HER2, human epidermal growth factor receptor 2; HGF, hepatocyte growth
factor; HR, hazard ratio; ID, invasive ductal; LVI, lymphovascular invasion; M0, no metastasis; PR, progesterone receptor; pT status, pathological
tumor status; OT, other types, including invasive lobular, mixed, micropapillary, mucinous, cribriform, tubular, metaplastic, clear cell, and
apocrine carcinoma
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years (95% CI, 9.8–16.2) for those with HGF high-
expressing tumors [hazard ratio (HR), 0.64 (95% CI,
0.49–0.84), P = 0.001]. Median OS was 9.1 years (95% CI,
7.7–10.6) for patients with CXCL12 (cytoplasm) low-
expressing tumors and 15.3 years (95% CI, 12.3–18.3) for
those with CXCL12 (cytoplasm) high-expressing tumors
[HR, 0.63 (95% CI, 0.45–0.87), P = 0.005] (Fig. 4). In the
subgroup analysis, c-MET was correlated to OS in the
subgroups with patients older than 65 years at diagnosis,
PR low-expressing tumors, luminal B-like HER2− breast
cancer subtype, invasive ductal tumors, and histological
grade II tumors (see Additional file 8). CXCL12 (nu-
cleus), CXCR4 (cytoplasm), and CXCR4 (nucleus) were
not associated with OS in any patient or tumor sub-
group in the univariable analysis (see Additional files 9,
10, and 11). Based on these findings, we further classified
patients according to the expression of HGF and c-
MET. The median OS of patients with both HGF and c-
MET low-expressing tumors was 6.6 years (95% CI, 5.9–
7.3), which was shorter than the OS of the other sub-
groups (Fig. 5). Age at diagnosis, PR, and pT status were
the other parameters associated with OS (Fig. 3).
Discussion
In this unique cohort of male breast cancer patients, we
identified HGF expression in the primary tumor to be
an independent predictor for better OS in the non-
metastatic setting. In addition, high expression of
CXCL12 in the cytoplasm of tumor cells in the primary
tumor was associated with better OS.
Remarkably, the prognostic value of HGF and c-MET
is contradictory to the findings in female breast cancer.
In female breast cancer, HGF and c-MET have been
identified as a predictor for worse outcomes and are as-
sociated with a high Ki-67 labeling index [14, 16–19].
This led to the hypothesis that HGF acts as a mitogen in
female breast cancer [32]. In our cohort in male breast
cancer, we identified HGF to be an independent prog-
nostic factor for better OS.
The prognostic value of the CXCL12 expression in
male breast cancer is comparable with the findings in fe-
male breast cancer reported in the literature [33, 34]. In
female breast cancer, the cytoplasmic expression of
CXCL12 was associated with better disease-free survival
and OS [33, 34]. These results are confirmed by a re-
cently published meta-analysis, which included 8 studies
with a total of 2205 patients [35]. Four of these studies
(N = 953) measured the CXCL12 protein expression
which was positively correlated with disease-free survival
and OS.
The remarkable difference in the prognostic value of
HGF and c-MET compared to female breast cancer
might result from differences in tumor and environment
biology between male and female breast cancer. This is
in line with a recent study of DNA sequencing analysis
on 1943 cancer-related genes in 135 patients with male
breast cancer, which demonstrated differences in the
genomic landscape between male and female breast can-
cers. Somatic mutations in homologous recombination
deficiency-related genes were more prevalent in male
breast cancer compared to female breast cancer, whereas
TP53 somatic mutations were less frequent [36]. Cur-
rently, it becomes clear that some important markers in
breast cancer biology can play a different role in male
compared to female breast cancer. When dependency
patterns of key oncoproteins were compared between
134 male and 728 female breast cancer tissues, some
similar patterns were observed for both genders, such as
p53 and hypoxia-inducible factor 1-alpha [8]. However,
also clear differences were identified. For example, the
Fig. 4 Kaplan-Meier analysis for the overall survival of M0 patients at diagnosis classified by HGF and CXCL12 (cytoplasm) tumor expression.
CXCL12, C-X-C motif chemokine 12; HGF, hepatocyte growth factor; M0, no metastasis
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expression of PR showed in female breast cancer a con-
tinuous dependency on cytokeratin 8/18, cyclin D1, B
cell lymphoma 2 (Bcl-2), and cyclin-dependent kinase
inhibitor p21 [8]. In male breast cancer, however, PR
showed no dependency on these markers, indicating that
PR is subject to effects from other markers [8]. AR had a
stronger effector function in males compared to female
tumors [8]. Results from the 21-gene breast recurrence
score, used to characterize the molecular features of
breast cancer, also indicate distinct differences in male
compared to female breast cancer. Men below 40 years
of age had a higher recurrence score compared to fe-
males while above 60 years men had a larger proportion
with a low recurrence score [10]. Therefore, although
differences between male and female breast cancer be-
come apparent, the crosstalk among predominant bio-
logic pathways and their function in males is not well
understood, including that of the HGF/c-MET signaling.
In female breast cancer, HGF/c-MET promotes cell
proliferation, migration, and invasion by HGF binding-
induced c-MET activation of the phosphoinositide 3-
kinase/Akt pathway and the Erk/mitogen-activated protein
kinase cascade [14]. Furthermore, high expression of HGF
or c-MET was associated with higher histological tumor
grade and worse patient outcomes [16, 19]. In the present
study, higher expression of both HGF and c-MET was asso-
ciated with improved OS. One possible factor contributing
to this difference might be the age difference between male
and female breast cancer patients. Preclinical evidence
suggests that with advancing age, the tumor stroma exhibits
alterations, such as decreased interferon signaling and anti-
gen presentation. These changes may influence the prolifer-
ative effects of the tumor microenvironment [37]. The
influence of age on the tumor microenvironment needs to
be further elucidated but might lead to new insight into the
dynamics of the tumor microenvironment.
Our study has limitations. First, due to its retrospective
nature, data of some patient and tumor characteristics are
missing. Nevertheless, the number of M0 patients ex-
cluded for the OS analysis was limited, and therefore, a
significant impact on our findings appears unlikely. Sec-
ond, currently, there is no widely accepted standardized
methodology for immunohistochemical staining and the
scoring of the studied markers. This may create bias in
interpreting the data. These issues can be addressed in the
prospective Male Breast Cancer Program prospective part
(NCT01101425), which has finalized the inclusion and of
which analyses are ongoing.
Conclusions
In the present study, HGF and CXCL12 tumor expres-
sion identified male breast cancer patients with good
prognosis. Whether this insight provides possible op-
tions for intervention strategies should be determined in
future studies.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13058-020-01266-x.
Additional file 1: Table S1. Pattern of treatment for 487 patients
without metastasis at diagnosis.
Additional file 2: Figure S1. Examples of negative and positive
staining of CXCR4; negative, weak (1+) and strong (2+) staining of
CXCL12, HGF and c-MET by immunohistochemistry. Abbreviations:
CXCL12, C-X-C motif chemokine 12; CXCR4, C-X-C chemokine receptor
type 4; HGF, hepatocyte growth factor.
Fig. 5 Kaplan-Meier analysis for overall survival of M0 patients at diagnosis classified by HGF and c-MET tumor expression. CI, confidence interval;
HGF, hepatocyte growth factor; HR, hazard ratio; M0, no metastasis
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Additional file 3: Table S2. The concordance rates of the percentage/
H-score for each TMA core among the studied markers between the two
observers.
Additional file 4. Information on the heterogeneity of percentage of
positive cells for CXCR4 between the TMA cores.
Additional file 5. Information on the heterogeneity of H-score for
CXCL12 between the TMA cores.
Additional file 6. Information on the heterogeneity of H-score for HGF
between the TMA cores.
Additional file 7. Information on the heterogeneity of H-score for c-
MET between the TMA cores.
Additional file 8: Figure S2. Subgroup analysis by patient and tumor
characteristics of the prognostic value of c-MET for overall survival in pa-
tients without metastasis. c-MET is associated with overall survival in the
subgroups with patients older than 65 years at diagnosis, PR low expres-
sion tumors, Luminal B-like HER2- breast cancer subtype, invasive ductal
tumors and histological grade II tumors. Abbreviations: AR, androgen re-
ceptor, CI, confidence interval; ER: estrogen receptor; HR, hazard ratio; PR,
progestrone receptor; pT status: pathological tumor status.
Additional file 9: Figure S3. Subgroup analysis by patient and tumor
characteristics of the prognostic value of CXCL12 (nucleus) for overall
survival in patients without metastasis. CXCL12 (nucleus) is not associated
with overall survival in any subgroup. Abbreviations: AR, androgen
receptor, CI, confidence interval; CXCL12, C-X-C motif chemokine 12; ER:
estrogen receptor; HR, hazard ratio; PR, progestrone receptor; pT status:
pathological tumor status.
Additional file 10: Figure S4. Subgroup analysis by patient and tumor
characteristics of the prognostic value of CXCR4 (cytoplasm) for overall
survival in patients without metastasis. CXCR4 (cytoplasm) is not
associated with overall survival in any subgroup. Abbreviations: AR,
androgen receptor, CI, confidence interval; CXCR4, C-X-C chemokine re-
ceptor type 4; ER: estrogen receptor; HR, hazard ratio; PR, progestrone re-
ceptor; pT status: pathological tumor status.
Additional file 11: Figure S5. Subgroup analysis by patient and tumor
characteristics of the prognostic value of CXCR4 (nucleus) for overall
survival in patients without metastasis. CXCR4 (nucleus) is not associated
with overall survival in any subgroup. Abbreviations: AR, androgen
receptor, CI, confidence interval; CXCR4, C-X-C chemokine receptor type
4; ER: estrogen receptor; HR, hazard ratio; PR, progestrone receptor; pT
status: pathological tumor status.
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FFPE: Formalin-fixed paraffin-embedded; HER2: Human epidermal growth
factor receptor 2; HGF: Hepatocyte growth factor; HR: Hazard ratio;
HRP: Horseradish peroxidase; IQR: Interquartile range; OS: Overall survival;
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